Biomarkers in Patients With Advanced Rhabdomyosarcoma

Children's Oncology Group

Status: Completed

Conditions: Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Childhood Alveolar Rhabdomyosarcoma; Stage IV Adult Soft Tissue Sarcoma; Adult Rhabdomyosarcoma; Childhood Embryonal Rhabdomyosarcoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Rhabdomyosarcoma

Treatments: Other: Laboratory Biomarker Analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01668095

NCI-2012-01997 (Registry Identifier)

COG-ARST12B8 (Other Identifier)

CDR0000738499 (Other Identifier)

ARST12B8 (Other Identifier)

Details and patient eligibility

About

This research trial studies tumor tissue to identify important proteins and biomarkers from patients with rhabdomyosarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.

Full description

PRIMARY OBJECTIVES:

I. To investigate whether the expression of a subset of proteins (by immunohistochemistry), known to be Involved in the paired box (Pax)3, Pax7, and Patched-1 neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar and embryonal rhabdomyosarcomas.

OUTLINE:

Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.

Enrollment: 10 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• 8 tissue microarrays (TMA) slides of the following diseases available:

  • Alveolar rhabdomyosarcoma
  • Embryonal rhabdomyosarcoma
  • Anaplastic rhabdomyosarcoma

Trial design

10 participants in 1 patient group

Ancillary-Correlative (biomarker analysis)

Description:

Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.

Treatment:

Other: Laboratory Biomarker Analysis